

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 39/395, 37/02, 31/70 A61K 37/48	A1	(11) International Publication Number: WO 92/17206 (43) International Publication Date: 15 October 1992 (15.10.92)
(21) International Application Number: PCT/GB92/00570 (22) International Filing Date: 30 March 1992 (30.03.92) (30) Priority data: 9106678.7 28 March 1991 (28.03.91) GB (71) Applicant (for all designated States except US): THE VICTORIA UNIVERSITY OF MANCHESTER [GB/GB]; Oxford Road, Manchester M13 9PT (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : FERGUSON, Mark, William, James [GB/GB]; FOREMAN, David, Michael [GB/GB]; Department of Cell & Structural Biology, University of Manchester, Coupland III Building, Manchester M13 9PT (GB). SHAH, Mamta [IN/GB]; 12 Lathom Road, Withington, Manchester M20 9NX (GB). (74) Agents: McNEIGHT, David, Leslie et al.; McNeight & Lawrence, Regent House, Heaton Lane, Stockport, Cheshire SK4 1BS (GB).		(81) Designated States: AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC (European patent), MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, PL, RO, RU, SD, SE (European patent), SN (OAPI patent), TD (OAPI patent), TG (OAPI patent), US. Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: WOUND HEALING (57) Abstract A composition for use in the treatment of wounds to inhibit scar tissue formation during healing is disclosed, comprising an effective activity-inhibiting amount of a growth factor neutralising agent or agents specific against only fibrotic growth factors together with a pharmaceutically acceptable carrier. The method of preparation of said composition and method of administering the composition to a host suffering from tissue wounding is also disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCI on the front pages of pamphlets publishing international applications under the PCI.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	RU	Russian Federation
CG	Congo	KP	Democratic People's Republic of Korea	SD	Sudan
CH	Switzerland	KR	Republic of Korea	SE	Sweden
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
DE	Germany	MC	Monaco	TG	Togo
DK	Denmark			US	United States of America

WOUND HEALING

This invention relates to the healing of wounds and to agents and techniques for facilitating repair and healing of animal tissue, especially, but not exclusively, skin or other epithelial tissue, that has been damaged by, for example, wounds resulting from accidental injury, surgical operations or other trauma. The invention has particular reference to the healing of wounds in humans and other vertebrates.

As is well known, the healing of wounds in tissue such as skin generally involves, at least in adult humans and other mammals, a process of extra-cellular matrix (ECM) biosynthesis, turnover and organisation which commonly leads to the production of fibrous, connective tissue scars and consequential loss of normal tissue function.

In the realm of surgery scar tissue formation and contraction is a major clinical problem for which there is no entirely satisfactory solution at present. Likewise, scarring and fibrosis following accidental burning or other injuries or trauma, particularly in children, often has serious results, leading to impaired function, defective future growth, and to unsightly aesthetic effects, and again presents a major problem.

- 2 -

In regard to unsightly aesthetic effects produced by scars, there also commonly arises a need for cosmetic treatment or operations to attempt to remove these disfigurements in order to improve appearance. Additionally, a similar need for cosmetic treatment often arises in connection with unwanted tattoos and other skin blemishes. At present, however, it is difficult or impossible to carry out such cosmetic treatment or operations satisfactorily since a certain amount of surgery is generally involved which in itself is likely to result in wounds producing fresh unsightly scar tissue.

In adult humans and other mammalian vertebrates, wound healing in tissues such as skin is generally a reparative process, in contrast to a regenerative process which appears to take place in healing of fetal and embryonic tissue. The outcome of a wound repair process appears to be influenced by a number of different factors, including both intrinsic parameters, e.g. tissue oxygenation, and extrinsic parameters, e.g. wound dressings. There is, however, considerable evidence indicating that the overall process of healing and repair of wound damaged tissue, including the necessary intercellular communication, is regulated in a coordinated manner in adult humans and other mammals by a number of specific soluble growth factors which are

- 3 -

released within the wound environment (especially by degranulating platelets and incoming macrophages) and which, amongst other things, appear to induce neovascularisation, leucocyte chemotaxis, fibroblast proliferation, migration and deposition of collagen and other extracellular matrix molecules within the wounds. Such growth factors that have been identified and isolated are generally specialised soluble proteins or polypeptides and include transforming growth factor alpha (TGF- α), transforming growth factor beta (TGF- β 1, TGF- β 2, TGF- β 3 etc), platelet derived growth factor (PDGF), epidermal growth factor (EGF), insulin-like growth factors I and II (IGFI and IGFI) and acidic and basic fibroblast growth factors (acidic FGF and basic FGF). Many of these growth factors have already been made by genetic engineering using recombinant DNA technology.

General reviews of these growth factors are to be found in articles by Mary H McGrath in Clinics in Plastic Surgery, Vol. 17, No. 3, July 1990, pp 421-432, and by George A Ksander in Annual Reports in Medicinal Chemistry, 1989, Chap, 24 (published by Academic Press, Inc.) of which the contents are incorporated herein by reference.

The recognition of the importance of the role of such growth factors in the control of wound healing has

- 4 -

led to numerous proposals for their clinical use and application as exogenous growth factor agents in treatment for acceleration and promotion of healing of wounds, especially in cases of defective wound healing states (see for example Sporn et al, Science (1983) 219, 1329-1331; Brown et al, J. Exp. Med. (1986) 163, 1319-1324; Mustoe et al, Science (1987) 237, 1319-1324), and this has been the main trend in endeavouring to develop therapeutic applications of the knowledge acquired about these growth factors.

According to the present invention there is provided a composition for use in the treatment of wounds to inhibit scar tissue formation during healing, comprising an effective activity-inhibiting amount of a growth factor neutralising agent or agents specific against only fibrotic growth factors together with a pharmaceutically acceptable carrier.

The TGF- β growth factor family, for example, is believed to have a particularly important regulating role in wound repair, especially in adult animals, as a stimulant of macrophage infiltration, fibroblast migration, and extracellular matrix synthesis, especially collagen synthesis and deposition by fibroblasts which are involved in the production of scar tissue. Other growth factors, e.g. PDGF, are also important in this process and, to some extent, are

- 5 -

believed to act in cooperation with one another in the complex overall regulatory process that is involved in wound healing. Indeed, PCT/US90/05566 discloses the general use of antibodies to TGF- β to reduce fibrosis in a rat kidney nephrosis induced model. However, it is now found that not all TGF- β growth factors are fibrotic and that suppressing the activity of TGF β -3 in particular is counter-productive.

PCT/US90/05566 mentions TGF β -1 and TGF β -2 as having the function of increasing extracellular matrix production, but does not suggest that any particular TGF β does not have such an effect.

The growth factor neutralising agent may be a growth factor neutralising antibody, for example antibodies to TGF- β 1, TGF- β 2 and PDGF.

The growth factor neutralising agent may be a growth factor receptor blocking agent, for example a peptide containing the receptor binding site of the growth factors TGF- β 1, TGF- β 2 or PDGF, for example.

The growth factor neutralising agent may also comprise a molecule which binds to the growth factor to inhibit receptor binding, for example where the growth factor is selected from TGF- β 1 and TGF- β 2, the molecule may be selected from Decorin and Biglycan.

- 6 -

The growth factor neutralising agent may also be an antisense oligonucleotide or ribosyme(s) to growth factor mRNA, which both act to prevent mRNA from being translated.

The growth factor neutralising agent may also be a soluble form of the receptor or the growth factor binding domain of the receptor.

The growth factor neutralising agent may be present in the composition in an active form. Alternatively, the growth factor neutralising agent may be present in an inactive form.

One method of inactivating the growth factor neutralising agent is encapsulation, whereby the capsules may be degradable by an external stimulus to release the active growth factor neutralising agent when required.

The external stimulus may include UV light, in vivo enzymes, ultrasound or heat.

A second method of inactivating the growth factor neutralising agent may be by the molecular addition of a binding molecule.

- 7 -

Again, the binding molecule may be detached from the complex to release active growth factor neutralising agent by an external stimulus including UV light, in vivo enzymes, ultrasound or heat.

The pharmaceutically acceptable carrier may comprise a neutral sterile cream, gel or powder for topical application, or a sterile solution for injection, irrigation or inhalation or an aerosol, or may comprise a sterile dressing for topically covering a wound or may be in the form of a tablet or capsule for enteral administration, or the carrier may comprise a biopolymer patch or a slow release device for implantation.

The composition may also comprise active cytokines, for example fibroblast growth factor or factors or other cell proliferation or migration stimulating or glyco-aminoglycan stimulating factors in a ratio sufficient to accelerate wound healing in addition to the growth factor neutralising agent(s) reducing wound scarring.

The invention also provides a method of preparation of a pharmaceutical composition containing the growth factor neutralising agent or agents for applying the composition topically in a cream, gel, powder or dressing; in a solution for injection, irrigation or inhalation or aerosol, or in the form of a tablet or capsule for enteral administration. The

pharmaceutical preparation may also comprise a biodegradable polymer forming a patch, or an implantable control release device, useful in surgical operations having a large initial release followed by a slower release later. It will be appreciated that this list is not exhaustive, many other types of compositions being possible, such as might readily occur to one skilled in the art.

The method of preparation of the composition may also include a composition comprising active cytokines.

The invention also provides a method of inhibiting scar tissue formation during the healing of wounds, said method consisting in administering to a host suffering from tissue wounding a growth factor neutralising agent or agents in the wound area in a dosage effective to reduce activity of one or more growth factors involved in the process that leads to the formation of scar tissue during healing.

Preferably, the inhibitory agent or mixture of agents employed for this purpose comprises a neutralising antibody or antibodies specific to one or more of the growth factors concerned, or to precursors of such growth factors. Advantageously, such antibody or each such antibody, is a monoclonal antibody obtained by

- 9 -

recombinant DNA techniques. However, polyclonal antibodies, purified for example by affinity chromatography from antiserum prepared by injection of relevant growth factor(s) in an appropriate host, may also be used quite satisfactorily as an alternative, as has been the case in most of the preliminary experimental investigations. If desired, instead of complete antibodies, fragments thereof (Fab's) retaining the specific antigen binding characteristics can also be used and such fragments are intended to be included within the scope of the term "antibody" as used herein in this specification.

In regard to precursors of these growth factors, it is known that in many cases the growth factors are initially present in an inactive state as part of, or as a ligand bound to, a larger protein molecule, and are separated from the latter, e.g. by enzymic action, when released in their active form. Binding of a neutralising agent such as an antibody to such inactive protein precursors may therefore prevent or inhibit proteolytic action and release of the active growth factors which will lead to an overall neutralising effect and inhibition of activity in the same way as the alternative process of a direct binding of an inhibitory agent to the active growth factor molecules themselves or to cellular receptor sites of such growth factors.

- 10 -

Instead of using growth factor neutralising antibodies, the inhibitory agent or mixture of agents may alternatively consist of a synthetic peptide or peptides that can act to antagonise or block growth factor activity, e.g. by blocking binding of the growth factor(s) at cellular receptor sites without eliciting any intracellular "second messenger" response. Such peptide "blocking" agents could have the advantage of being free of potential adverse immunogenic effects, and may pass through membrane barriers more easily than antibodies so that they would be most suitable for making up pharmaceutical formulations or compositions for topical application. These "blocking" peptides may readily be designed from knowledge of the amino acid sequence of the growth factors concerned and of that portion of this sequence which is involved in binding to the cellular receptors since these peptides will need to "mimic" this binding portion of the sequence. It is, for instance, known that with TGF- β 1 it is the c-terminal region of the molecule that is involved in receptor binding. Similarly, the region(s) involved in receptor binding with TGF- α is the region between cys 33 and cys 42, and with EGF it is the regions between cys 20 and cys 31, between tyrosine 14 and cys 31 and between leucine 15 and arginine 53 that are involved. With FGF's the critical receptor binding region is that between amino acids 105 and 115.

- 11 -

As a further possibility, the inhibitory growth factor neutralising agent(s) may consist of other molecular entities that act by binding directly to a growth factor or factors, or precursor(s) thereof, to inactivate the latter. An example of a neutralising or inhibitory agent of this kind is Decorin which is a small chondroitin-dermatan sulphate proteoglycan known to strongly bind TGF- β , as reported by Yamaguchi et al, Nature (1990), 346, 281-284.

Alternatively, the inhibitory growth factor neutralising agent(s) may be active at the molecular level and consist of molecules active against a growth factor's mRNA. Such molecules may include antisense oligonucleotide(s) synthesised against one or more growth factor mRNA sequences to prevent translation thereof, or the molecule may be a ribosyme(s) targetted against specific sequences of one or more growth factor mRNA sequences to destroy the mRNA and again prevent its translation.

Although use of an antibody or other agent having a neutralising effect in respect of only one growth factor that is involved in the formation of scar tissue during wound healing, especially TGF- β 1 and 2 or PDGF for example, may be quite sufficient to prevent any significant amount of scar tissue from being produced.

- 12 -

In some cases combined administration of two or more different antibodies or other inhibitory agents having a neutralising effect against two or more different growth factors concerned may be found to be even more effective, especially for relatively large excisional wounds for example. In this case, the different or other inhibitory agents may be administered separately but simultaneously or sequentially, or they may be made up into a mixture or "cocktail" within a single pharmaceutical formulation.

Although it is believed that a series of these growth factors, including at least those of the TGF- β family and PDGF, normally act in cooperation with one another in an orchestrated manner to regulate the overall process of wound healing, including the steps leading to the production of scar tissue, the effect on production of scar tissue of reducing or neutralising activity of any one growth factor is likely to vary depending on the nature or identity of that growth factor and on the form of the resultant active growth factor profile. Thus, whilst inhibition of the activity of TGF- β and/or PDGF can generally be very effective in this respect, inhibition of the activity of certain of the other growth factors may, at least on its own, be less effective under similar conditions for reducing scar tissue formation, even though such other growth

- 13 -

factors may still be necessary, or may at least have a beneficial effect, in connection with promoting wound healing.

There can therefore be a further possibility in applying the invention of using an inhibitory or neutralising agent or agents effective in reducing activity of a growth factor or factors e.g. TGF- β and/or PDGF, having a major role in the formation of scar tissue in combination with a different exogeneous growth factor or agent which does not independently promote the formation of scar tissue to any significant extent but which, at the same time, can independently promote wound healing or provide a beneficial effect in respect of quality of healing. At least in some cases, such other additional exogeneous growth factor, for use in combination with TGF- β or PDGF neutralising agent(s) for example, may be provided by fibroblast growth factors (FGF's). Thus, by providing a pharmaceutical preparation having a ratio of the active cytokine FGF to TGF- β and/or PDGF neutralising agent(s), a preparation may be obtained which not only prevents scarring of a wound, but also accelerates the whole process of wound healing.

- 14 -

It might have been anticipated that any treatment for reducing or preventing scar tissue formation would be most effectively applied at a relatively late stage of healing during the phase of tissue remodelling or reorganisation that occurs subsequent to the formation of granulation tissue which replaces fibrin initially produced in the early stages of healing. Contrary to such expectation, however, it has been found, surprisingly, that in applying the present invention the treatment with the growth factor neutralising agent or agents may need to be carried out at an early stage of healing in order to be effective. In general, the treatment is best carried out before and/or during the granulation phase whilst fibrin is still present, i.e. before the fibrin has been wholly replaced by granulation tissue. This will usually be within a period of about 14 days after the initial occurrence of a wound. Preferably, however, treatment will be commenced earlier, within seven days or, if possible, within three days or less following wounding. Indeed, it may often be most advantageous to commence treatment on the same day as wounding, or at least on the following day, and in the case of surgical wounds the commencement of this treatment, say by topical or parenteral application of the growth factor neutralising agent(s) in a pharmaceutical formulation applied to the wound area, may well be incorporated as an integral part

- 15 -

of the surgical procedure and be applied before surgery or immediately the main surgery is completed, before or after suturing.

It has also been found, again somewhat surprisingly, that the treatment does not necessarily need to be repetitive and to be continued throughout all the phases of wound healing. In order to be effective, it may often be sufficient to administer the growth factor neutralising agent(s) in an appropriate dosage once, or only a few times at most, during the early stages of wound healing. This is of course important where agents such as proteins are concerned which may tend to provoke immunological reactions, and it also gives other practical and economic advantages.

Although it is possible that in some cases the overall time to achieve complete healing of a wound may be somewhat extended upon applying this treatment, any increase in overall healing time may well be more than adequately compensated for by the improved quality of the healed wound. A noteworthy and further surprising feature of the experimental work so far conducted, however, is that no really significant increase in overall healing time has been observed, nor has there been any impairment of wound strength upon healing. Indeed, in respect of this latter point, it would seem

- 16 -

that wound strength may even be improved in that the orientation observed of the new collagen fibres or fibrils formed during healing, at least in the case of incisional dermal wounds, more closely resembled that of undamaged tissue, lying generally parallel to the outer skin surface instead of at a large angle or generally perpendicular to the outer surface as is commonly found when such wounds heal normally with formation of scar tissue.

By way of further background explanation and description of the invention, illustrative examples are hereinafter presented of some of the investigations made and results obtained in the development of the invention, from which the skilled person in the art will more readily be able to appreciate the nature thereof and to put the invention into practical effect.

First there follows an outline or summary of the materials, methods and techniques which have generally been used, unless subsequently stated otherwise, in the investigations and illustrative examples referred to.

The preliminary experimental work in these investigations was carried out using rats as model experimental animals, but the results are applicable generally to humans and other animals.

- 17 -

Adult, male, Sprague-Dawley rats weighing between 200-250 grammes were anaesthetised with halothane/nitrous oxide/oxygen inhalation. After locally clipping the fur, four linear full-thickness incisions, 10 mm in length, were made on the dorsal skin of the animal, equidistant from the midline and adjacent to its four limbs.

In each animal one wound (control) was unmanipulated, one (sham control) was injected with an irrelevant antibody, one (the positive control) was injected with a growth factor detailed below, and one (the experimental wound) was injected with a preparation of appropriate growth factor neutralising antibody or antibodies. The experiments were conducted on groups of these animals, and according to which group was concerned the injections (100 µl each) were carried out daily for either a period of three consecutive days or seven consecutive days, starting either on the day of wounding, or on the following day, or in a few groups at a much later stage, e.g. 7 days or 19 days post-wounding.

In each group, at least two animals were usually killed (by chloroform overdose on post-wounding days 7, 14, 28 and 42, and in some cases also on post-wounding days 70, 112 and 168. All four wounds were excised (with a 0.5 cm margin on all sides) immediately after

- 18 -

death of each animal and were subjected to tissue analysis by conventional immunohistochemical, histological staining and biochemical techniques.

Generally, for carrying out this analysis, each wound was bisected to provide two samples which were either frozen and/or fixed and processed for immunocytochemical staining using antibodies to collagens I, III, IV, laminin and fibronectin or processed for routine histological examination using a variety of connective tissue stains, or they were immediately freeze-dried for biochemical analyses after microscopic dissection.

In the immunohistochemical analyses, primary and secondary antibodies for indirect immunostaining were used as shown in the following tables.

- 19 -

TABLE 1Primary Antibodies

<u>Raised</u> <u>Against</u>	<u>Host</u>	<u>Source</u>	<u>Dilution</u>	<u>Secondary Ab</u> <u>(Table 2 ref)</u>
HUMAN FIBRONECTIN	SHEEP	<u>a</u>	1:100	1
MOUSE LAMININ	RABBIT	<u>b</u>	1:50	2
RAT TYPE I COLLAGEN	RABBIT	<u>b</u>	1:50	2
RAT TYPE III COLLAGEN	RABBIT	<u>b</u>	1:50	2
RAT TYPE IV COLLAGEN	RABBIT	<u>b</u>	1:100	2
RAT MACROPHAGES	MOUSE	<u>a</u>	1:200	3 & 4
RAT MONOCYTES & MACROPHAGES	MOUSE	<u>a</u>	1:200	3 & 4
HUMAN FACTOR VIII	RABBIT	<u>c</u>	1:200	2

- 20 -

TABLE 2 Secondary Antibodies

Raised				
<u>Against</u>	<u>Host</u>	<u>Source</u>	<u>Dilution</u>	<u>(Table 1 ref)</u>
SHEEP IgG	DONKEY	<u>a</u>	1:40	1
RABBIT IgG	SWINE	<u>c</u>	1:40	2
MOUSE IgG	SHEEP	<u>d</u>	1:200	3
STREPTAVIDINE		<u>d</u>	1:100	4

Key to Source Codes

<u>a</u>	SEROTEC LTD, Oxford, UK.
<u>b</u>	Institut Pasteur de Lyon, France.
<u>c</u>	DAKOPATTS, Copenhagen, Denmark.
<u>d</u>	AMERSHAM, INTERNATIONAL Plc, Amersham, UK.

Note : Secondary antibodies 1, 2 and 4 were FITC conjugated (fluorescein isothiocyanate labelled) for immunofluorometric detection and measurement; 3 was biotynlated.

In carrying out the indirect immunostaining, the incubation with the primary antibody was for 1 hour followed by three rinses in phosphate buffered saline PBS. Incubation with FITC-conjugated secondary antisera was for 1 hour followed by a further three

- 21 -

rinse with PBS. Immunostaining for macrophages and monocytes involved the Biotin-Streptavidine technique, i.e. after the primary incubation and rinsing, the sections were incubated with the biotynlated sheep antimouse IgG for 1 hour, rinsed with PBS three times, incubated with the fluorescein streptavidine for 20 minutes and finally washed with PBS three times. The sections were mounted in a non-fading medium, DABCO (1,4-diazobicyclo-(2,2,2)-octane), and photographed using a Leitz Dialux microscope and kodak Ektachrome 400 ASA film.

For each primary antibody and each wound, control sections were stained, substituting PBS for the primary antibody.

In carrying out the routine histology staining, cellularity of the wounds was studied by staining cryosections of the tissue (post-fixed in Bouins fluid) with Harris's haematoxylin and eosin, and collagen deposition in the wounds was studied by staining cryosections with Masson's trichrome and Hughesdon's modification of Mallory's trichrome stains.

For the biochemical analyses, the wounds were microscopically dissected out along with a piece of unwounded dorsal skin from each wound and immediately

- 22 -

freeze-dried to constant weight. The tissue was homogenised in 1 ml of 1M guanidine hydrochloride, 0.15 M sodium acetate, 0.01 M EDTA, pH 5.8, for 24 hours at 4°C to extract the glycosaminoglycans. The homogenate was then centrifuged at 18,000 g for 1 hour. The pellet was washed twice with 0.5 ml of water and the washings added to the supernatant. The supernatant was dialysed against 100 mM phosphate buffer with 5 mM EDTA, pH 6.5, followed by digestion with papain 2.5 mg/ml. The glycosaminoglycans were precipitated with 2% CPC and separated using the method of Cappelletti et al, 1979.

After washing, the pellets were digested with pepsin 100 µg/ml in 0.5 M acetic acid at 4°C for 24 hours. This was followed by centrifuging at 18,000 g for 1 hour. The pellet thus obtained was subjected to Hydroxyproline assay as described by Stegman and Stadler (1987); some of the supernatant was also used for this assay. To measure the ratio of type I/III collagen, the supernatant was subjected to SDS PAGE using the method of Sykes et al (1976).

The growth factors used in these experiments were commercially available reagents obtained from R & D Systems (Mineapolis, U.S.A.) or British Biotechnology (U.K.) or Serotec (U.K.) and included :-

- 23 -

1. Transforming growth factor beta-1 (TGF- β 1) deriv d from porcine platelets - Dose 10 ng/injection.
2. Platelet derived growth factor (PDGF) from porcine platelets - Dose 10 ng/injection.
3. Epidermal growth factor (EGF) derived from mouse salivary gland - Dose 10 ng/injection.
4. Basic Fibroblast growth factor (bFGF) derived from bovine brain - Dose 10 ng/injection.
5. Acidic Fibroblast growth factor (aFGF) derived from bovine brain - Dose 10 ng/injection.

The growth factor neutralising antibodies used in these experiments were also reagents commercially available as detailed above and were of known neutralising potency. They included :

1. TGF Beta neutralising antibody (raised in rabbit against native porcine platelet TGF- β 1 - neutralises both TGF β -1 and TGF β -2) - Dose 50 μ g/injection.

- 24 -

2. PDGF neutralising antibody (raised in goats against native human PDGF) - Dose 20 µg/injection.
3. EGF neutralising antibody (polyclonal antibody raised in mouse against human EGF) - Dose 10 µg/injection.
4. Basic FGF neutralising antibody (raised in rabbits against native bovine brain basic FGF) - Dose 30 µg/injection.
5. Acidic FGF neutralising antibody (raised in rabbit against native bovine brain acidic FGF) - Dose 30 µg/injection.

The irrelevant antibodies used for the sham control wounds were either rabbit IgG or goat IgG according to the host in which neutralising antibody to the growth factor was raised. The dose of the irrelevant antibody was similar to that of the neutralising antibody.

Summary of Results

In all the experiments conducted, no differences were found between the control and sham control wounds

- 25 -

at any of the timepoints at which the wounds were examined, thereby indicating an absence of any major effects being produced by the introduction of foreign proteins. Also, no wounds showed impaired healing and the rate of epithelialisation was similar in all treatments.

However, at least in the case of the experimental wounds treated with the neutralising antibodies to TGF- β and PDGF major effects were produced provided treatment was commenced whilst the wounds were still fresh, preferably at or soon after the time of wounding, before or during the granulation phase. Thus, although no major differences were observed between the control wounds and the experimental wounds when treatment was not commenced until the 19th day post-wounding, in other cases, especially when treatment was commenced on the same day as wounding or on the following day, the experimental wounds contained much less collagen I and III compared to the other three wounds in the same animal at any timepoint. There was much greater spacing between the collagen fibrils but their orientation was almost identical to that of normal skin. Indeed, in the neutralising antibody treated wounds, it was often difficult to detect the site of the latter (except for the loss of ectodermal hair follicles). This was in sharp contrast to the other

- 26 -

wounds which showed a distinct scar with vertically orientated, parallel, and densely packed collagen fibrils. These effects were most marked in the papillary dermis and subcutaneous tissues. Wounds treated with neutralising antibodies to TGF- β or PDGF also showed a marked reduction in fibronectin, particularly in the reticular dermis, with an orientation pattern similar to that of the collagen fibrils. Although fibronectin staining was markedly reduced throughout the wound, it was still brightest at the dermal/epidermal junction. Treatment with neutralising antibodies to TGF- β and PDGF also decreased the number of blood vessels, monocytes and macrophages within the healing wound. By contrast, the positive control wounds treated with TGF- β and PDGF showed a marked increase in extracellular matrix accumulation, in the density of extracellular matrix packing and in the number of blood vessels, monocytes and macrophages. Scarring was more prominent in these growth factor treated wounds compared to controls.

These results demonstrate the ability of neutralising antibodies to selected growth factors markedly to reduce scar tissue formation in adult dermal wound healing. Most importantly, this advantageous effect was not accompanied by attendant problems of delayed wound healing or delayed epithelialisation and low wound strength.

- 27 -

Some improvement in reducing scar tissue formation was also observed after administering neutralising antibodies to fibroblast growth factors (FGF's) although in the preliminary experimental work it was less marked than in the case of neutralising TGF- β and PDGF growth factors. Interestingly, exogenous acidic or basic FGF itself seemed to improve scarring. It is, however, believed that similar results to TGF- β and PDGF may be achieved, although perhaps to a somewhat lesser extent, with neutralising agents to other growth factors administered at an appropriate dosage level under suitable conditions.

In the case of TGF- β at least, which appears to be highly active in connection with the production and organisation of collagen, especially collagen I, leading to the formation of scar tissue, it is believed that normally after the initial injury the level of this growth factor in the environment of the wound may increase quite quickly by means of an auto-catalytic cascade effect. Thus, not only does the TGF- β present within an initial wound from platelet degradation act as a chemoattractant to monocytes, macrophages and fibroblasts at increasing concentrations, but it also feeds back on its own promoter to stimulate its own synthesis so that high levels can soon arise. The inflammatory cells, especially macrophages, release

- 28 -

TGF- β and exhibit this auto-inductive effect on TGF- β synthesis. TGF- β also stimulates the synthesis and release of other growth factors, e.g. TGF- α , PDGF, EGF. TGF- β , and these other growth factors stimulate the synthesis of extracellular matrix molecules, e.g. collagens and glycosaminoglycans, by the wound fibroblasts and also influence the degree of proteolytic turnover and organisation of these extracellular matrix molecules. As the initial fibrin clot is dense, fibroblasts from the adjacent normal skin initially migrate up and down between the clot and the wound margin in a direction broadly perpendicular to the basement membrane. The collagen and other extracellular matrix molecules are also deposited in this abnormal orientation and this eventually gives rise to the scar.

It can be hypothesised that normal wound healing in adults is phylogenetically optimised for speed of closure in adverse healing conditions. Consequently, the quantities of growth factor released are generally excessive, giving the speed of the healing process considerable buffering against external noxious factors but with the long term disadvantage of scarring. Modern methods of wound care, e.g. bandages, and reduction in risks of infection have largely eliminated the necessity of this growth factor "overdrive" so that treatment to diminish the active growth factor profile is permissible and will minimise subsequent scarring.

- 29 -

Thus the autocatalytic cascade of events, described above for TGF- β , is reduced by treatment at an early stage with a neutralising agent. The latter, however, will not be applied in an amount sufficient to neutralize all of this growth factor, thereby leaving sufficient to enable wound healing to proceed without serious inhibition. A similar explanation is also applicable to at least PDGF.

Practical Usage

It will be appreciated that the results obtained from the investigations made in development of this invention have direct practical application in clinical use for controlling scar tissue formation in wound healing, either in therapeutic or cosmetic fields. For practical use, in general an appropriate amount of growth factor antibody or antibodies or other growth factor inhibitory agent(s), constituting the material effective in neutralising and/or in modifying the profile of relevant growth factors active and responsible for scar tissue formation in the healing of wounds, will be made up by any of the methods well-known in the art of pharmacy as a pharmaceutical formulation or preparation for administration in any suitable manner to a patient in need of wound treatment. Such pharmaceutical formulations or preparations may, moreover, be presented

- 30 -

not only individually for clinical use but they may also be presented as components of first aid kits for example for non-clinical emergency use.

By way of example in relation to TGF- β and PDGF growth factors, in general the antibody or antibodies or other neutralising agent(s) should be administered (at least for incisional wounds) so as to effectively neutralise between 1 pg - 1 μ g TGF- β (1 and 2) and/or PDGF (but preferably an amount of between 100 pg - 10 ng) per cm linear incision per administration. As previously indicated, application early in the wound healing process is essential. Normally this will be before, during or before and during, the phase of granulation tissue formation, within about 14 days, but preferably within 7 or 3 days, or less, following wounding.

The pharmaceutical preparations may conveniently be applied topically by application to the surface around the wound in liquid, gel, aerosol, cream or powder form, or in the form of a dressing, biodegradable patch or control release implantable device at the time of wounding or shortly thereafter. Parenteral administration, especially subcutaneous injection, may also often be preferred so that the neutralising antibody or antibodies or other agents

- 31 -

can be introduced directly into the wound environment for maximum efficiency. For this purpose the pharmaceutical formulations prepared may comprise sterile liquid preparations (e.g. in phosphate buffered saline) of a predetermined amount of the active material, e.g. relevant antibody or antibodies, presented in unit dosage form and contained in sealed ampoules ready for use. For the alternative topical mode of administration, however, which will be preferred in some cases, the formulations may be made up with the active material in intimate association or admixture with at least one other ingredient constituting a compatible pharmaceutically acceptable carrier, diluent or excipient in order to provide a composition, such as a cream, gel, ointment or the like, which is most suitable for topical application. The formulation may be applied to a sterile dressing, biodegradable/absorbable patches or dressings for topical application, or to slow release implant systems with a high initial release decaying to a slow release.

The formulation may also consist of a neutralising agent, for example, relevant antibody or antibodies, attached to a carrier, for example, a biopolymer of collagen or hyaluronic acid or a polymer, for example, PVC, from which it can be released quickly initially and more slowly in the longer term when

- 32 -

applied to, or implanted within, the wound or tissue viod.

As will be seen, the invention provides a number of different aspects and, in general, it embraces all novel and inventive features and aspects herein disclosed, either explicitly or implicitly and either singly or in combination with one another. Moreover, the scope of the invention is not to be construed as being limited by the illustrative examples or by the terms and expressions used herein merely in a descriptive or explanatory sense.

- 33 -

CLAIMS

1. A composition for use in the treatment of wounds to inhibit scar tissue formation during healing, comprising an effective activity-inhibiting amount of a growth factor neutralising agent or agents specific against only fibrotic growth factors together with a pharmaceutically acceptable carrier.
2. A composition according to claim 1, wherein the growth factor neutralising agent is a growth factor neutralising antibody.
3. A composition according to claim 2, wherein the growth factor neutralising antibody is selected from anti-TGF- β 1 antibody, anti-TGF- β 2-antibody and anti-PDGF-antibody.
4. A composition according to claim 1, wherein the growth factor neutralising agent is a growth factor receptor blocking agent.
5. A composition according to claim 4, wherein the growth factor receptor blocking agent is a peptide containing the receptor binding site of the growth factor.

- 34 -

6. A composition according to claim 5, wherein the peptide contains the receptor binding site for TGF- β 1 or TGF- β 2 or PDGF.

7. A composition according to claim 1, wherein the growth factor neutralising agent is a molecule which binds to the growth factor to inhibit receptor binding.

8. A composition according to claim 7, wherein the growth factor is selected from TGF- β 1 and TGF- β 2 and the molecule is selected from Decorin and Biglycan.

9. A composition according to claim 1, wherein the growth factor neutralising agent is an antisense oligonucleotide to growth factor mRNA.

10. A composition according to claim 1, wherein the growth factor neutralising agent is a ribosyme(s) active against growth factor mRNA.

11. A composition according to claim 1, wherein the growth factor neutralising agent is a soluble form of the receptor or the growth factor binding domain of the receptor.

12. A composition according to any preceding claim, wherein the growth factor neutralising agent is present in an active form.

- 35 -

13. A composition according to claims 1 to 11, wherein the growth factor neutralising agent is present in an inactive form.

14. A composition according to claim 13, wherein the growth factor neutralising agent is inactivated by being encapsulated.

15. A composition according to claim 14, wherein the capsules are degradable by an external stimulus to release the active growth factor neutralising agent when required.

16. A composition according to claim 15, wherein the external stimulus includes UV light, in vivo enzymes, ultrasound or heat.

17. A composition according to claim 13, wherein the growth factor neutralising agent is inactivated by the molecular addition of a binding molecule.

18. A composition according to claim 17, wherein the binding molecule is detached from and releases active growth factor neutralising agent by an external stimulus including UV light, in vivo enzymes, ultrasound or heat.

- 36 -

19. A composition according to any preceding claim, wherein the pharmaceutically acceptable carrier comprises a neutral sterile cream, gel, aerosol or powder for topical application.

20. A composition according to claims 1 to 18, wherein the pharmaceutically acceptable carrier comprises a sterile solution for injection, irrigation or inhalation.

21. A composition according to claims 1 to 18, wherein the pharmaceutically acceptable carrier comprises a sterile dressing for topically covering a wound.

22. A composition according to claim 21, wherein the dressing comprises a biodegradable/absorbable polymer.

23. A composition according to claims 1 to 18, wherein the pharmaceutically acceptable carrier comprises a biopolymer/polymer for implanting within the wound.

24. A composition according to any preceding claim, comprising active cytokines.

- 37 -

25. A method of preparation of a pharmaceutical composition containing the growth factor neutralising agent or agents specific against only fibrotic growth factors for applying the composition topically in a cream, gel, aerosol, powder, dressing or patch or in a solution for injection, irrigation or inhalation, or as a control release implant.


26. A method of preparation according to claim 25, wherein the composition comprises active cytokines.

27. A method of inhibiting scar tissue formation during the healing of wounds, said method consisting in administering to a host suffering from tissue wounding a growth factor neutralising agent or agents specific against only fibrotic growth factors in the wound area in a dosage effective to reduce activity of one or more growth factors involved in the process that leads to the formation of scar tissue during healing.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 92/00570

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl.5 A 61 K 39/395 A 61 K 37/02 A 61 K 31/70 A 61 K 37/48		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl.5	C 07 K C 12 P	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP,A,0282317 (AMGEN INC.) 14 September 1988, see page 17, lines 1-17 ---	1-2
X,P	WO,A,9110727 (LA JOLLA CANCER RESEARCH FOUNDATION) 25 July 1991, see page 7, line 2 - page 11, line 19 ---	1,4-8
A	EP,A,0258817 (BEHRINGWERKE) 9 March 1988 -----	
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
01-07-1992		GB 92/00570
International Searching Authority		Signature of Authorized Officer
EUROPEAN PATENT OFFICE		

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9200570

SA 57943

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 16/07/92. The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0282317	14-09-88	AU-A- 1715388	10-10-88
		JP-T- 1502669	14-09-89
		WO-A- 8807057	22-09-88
WO-A- 9110727	25-07-91	None	
EP-A- 0258817	09-03-88	DE-A- 3629640	03-03-88
		AU-B- 594496	08-03-90
		AU-A- 7766387	03-03-88
		JP-A- 63072630	02-04-88